Commercial Chinese polyherbal preparations combined with conventional therapy improve sleep quality in elderly patients with insomnia
A network meta-analysis of 19 RCTs involving 1851 participants found that commercial Chinese polyherbal preparations combined with conventional therapy significantly reduced PSQI scores (MD = -2.53, 95% CI [-3.62, -1.44]) and increased clinical effective rate (OR = 6.08, 95% CI [3.21, 11.51]) compared to conventional therapy alone. The evidence for effects on serum IL-6 was exploratory and limited.
Evidence Score
Study Evidence
Study 1. A network meta-analysis of commercial Chinese polyherbal preparations for insomnia in the elderly: focusing on sleep quality and the neuro-immune axis.
observationalLiang R, Zhang X, Li H, Li Z, Hu Y, Ma L, Liang Z, Liu X ยท Frontiers in pharmacology (2026)
Result:
Mechanism Graph
Limitations
- โ Risk of bias in included studies, particularly regarding blinding and outcome measurement
- โ Small number of studies for IL-6 analysis limits certainty of mechanistic findings
Frequently Asked Questions
What is the primary benefit of commercial Chinese polyherbal preparations for elderly insomnia?โผ
They significantly improve sleep quality as measured by PSQI scores when added to conventional therapy.
How large is the effect on PSQI score?โผ
The mean difference was -2.53 points, indicating a clinically meaningful improvement.
Do these preparations affect inflammatory markers?โผ
There is a preliminary trend toward reducing serum IL-6, but evidence is limited by few studies.
What is the recommended treatment duration?โผ
The abstract does not specify a duration; it varies across the included RCTs.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Liang R, Zhang X, Li H, Li Z, Hu Y, Ma L, Liang Z, Liu X. "A network meta-analysis of commercial Chinese polyherbal preparations for insomnia in the elderly: focusing on sleep quality and the neuro-immune axis.." Frontiers in pharmacology, 2026. PMID: 42630409 DOI: 10.3389/fphar.2026.1827554